EFM
TSHA icon

E Fund Management’s Taysha Gene Therapies TSHA Stock Holding History

E Fund Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149K Sell
21,814
-15,885
-42% -$94K ﹤0.01% 462
2026
Q1 		$169K Buy
+37,699
New +$175K 0.01% 457
2025
Q2 		$30.5K Buy
+13,214
New +$28.7K ﹤0.01% 394
2025
Q1 		– Sell
-17,844
Closed -$30.9K – 431
2024
Q4 		$30.9K Buy
+17,844
New +$37K ﹤0.01% 392

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

E Fund Management's TSHA Position: Q2 2026 in Review

E Fund Management reduced its Taysha Gene Therapies (TSHA) stake by 42% in Q2 2026, selling an estimated $94K and leaving 21,814 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #462.

E Fund Management first reported a position in TSHA in Q4 2024 and has held it in 4 quarters since. The position peaked at $169K in Q1 2026. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • E Fund Management held 21,814 shares of Taysha Gene Therapies worth $149K as of Q2 2026.
  • E Fund Management sold 15,885 Taysha Gene Therapies shares in Q2 2026, an estimated $94K.
  • Taysha Gene Therapies made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #462 holding.
  • E Fund Management first reported a position in Taysha Gene Therapies in Q4 2024 and has held it in 4 quarters since.
  • E Fund Management's Taysha Gene Therapies position peaked at $169K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.